Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

NCT07200102 | Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: 202511028
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy (anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitors (PI)) remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival. Selinexor is an exportin (XPO1) inhibitor with direct anti-tumor effect used often as an adjunct with other agents as bridging therapy prior to CAR-T. As selinexor does not affect T-cell yields or fitness, T-cell collection on selinexor for CAR-T manufacturing is safe. The aim of this study is to evaluate the safety and toxicity of selinexor in triple-exposed or refractory multiple myeloma patients with high-risk features (adverse risk cytogenetics, less than complete response (CR) post CAR-T, or extramedullary disease) following BCMA CAR-T therapy. The investigators hypothesize that selinexor as maintenance therapy following CAR-T has the potential to act synergistically with CAR-T cells leading to more durable responses.

Conditions

Multiple Myeloma

Keywords

Cilta-cel; Selinexor; Multiple Myeloma; Maintenance

Outcome Measures

Primary Outcomes (2)

• Rate of non-hematologic grade ≥ 3 treatment-related adverse events (excluding conditioning and CAR-T related adverse events) according to CTCAE v 6.0

  From start of selinexor through 30 days after the last dose of selinexor (estimated to be 13 months)

• Tolerability as measured by rate of patients who received > 80% of cumulative selinexor dose during the study period

  Through completion of selinexor treatment (estimated to be 12 months)

Secondary Outcomes (8)

• Rate of MRD negativity by clonoSEQ sensitive to 10-5

  At 6 months after CAR-T infusion

• Rate of MRD negativity by clonoSEQ sensitive to 10-5

  At 12 months after CAR-T infusion

• Rate of complete response (CR) and stringent CR (sCR) by IMWG response criteria

  At 6 months after CAR-T infusion

• Rate of complete response (CR) and stringent CR (sCR) by IMWG response criteria

  At 12 months after CAR-T infusion

• Progression-free survival (PFS)

  At 6 months after CAR-T infusion

Study Arms (1)

Selinexor

EXPERIMENTAL

Patients with high risk of relapse will receive maintenance selinexor starting at Day 30 (high risk MM patients) or after Day 58 (for MRD+ patients) post-cilta-cel infusion and will continue selinexor for up to 12 cycles. Selinexor will be given weekly on Days 1, 8, 15, and 22 of each 28-day cycle. The first 3 to 6 patients enrolled will be part of the safety run-in cohort; these patients will be monitored for dose-limiting toxicities during Cycle 1.

Drug: Selinexor

Interventions

Selinexor DRUG

Selinexor will be provided by Karyopharm Therapeutics, Inc.

Also known as: KPT-330, Xpovio

Selinexor

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of triple-class exposed or refractory multiple myeloma (MM). Diagnosis must be histologically confirmed. Patients with multiple myeloma with local amyloid deposition in the bone marrow are eligible. Only the following risk categories will be enrolled:
• High risk myeloma, defined by the presence of at least one of the following features:
• Deletion 17p and/or TP53 alteration:
• Deletion of 17p with a cancer clonal fraction (CCF) ≥20%, assessed on CD138-positive/purified plasma cells, AND/OR
• TP53 mutation identified using a validated next-generation sequencing (NGS)-based assay.
• High-risk IgH translocation with chromosome 1 abnormality:
• Presence of t(4;14), t(14;16), or t(14;20) in combination with either gain/amplification of 1q (1q+) and/or deletion of 1p32.
• Chromosome 1p32 deletion patterns:
• Monoallelic deletion of 1p32 occurring with gain/amplification of 1q, OR
• Biallelic deletion of 1p32.
• Elevated β2-microglobulin without renal dysfunction:
• Serum β2-microglobulin ≥5.5 mg/L in the setting of normal renal function, defined as serum creatinine \<1.2 mg/dL.
• Presence of extramedullary disease prior to receiving CAR-T OR
• Standard risk myeloma with MRD-positive (MRD+) disease at MRD draw around Day 58-60 post CAR-T.
• Received standard of care ciltacabtagene autoleucel (cilta-cel; Carvykti).

You may not qualify if:

• MM with active CNS involvement.
• Confirmed progressive disease by IMWG after CAR-T administration.
• Unresolved cytokine release syndrome (CRS) or CAR-T neurologic toxicity.
• Any unresolved non-hematologic grade ≥ 3 treatment-related toxicity from CAR-T.
• Administration or planned administration of any other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy which would be considered a treatment of multiple myeloma from Day 28 post-CAR-T cell therapy through discontinuation from study treatment. Note: patients may be on corticosteroids if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis)
• Has received selinexor or another XPO1 inhibitor post-CART.
• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
• Prior organ transplant requiring immunosuppressive therapy.
• Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial
• Currently receiving any other investigational agents.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor or other agents used in the study.
• Active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.
• Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1 of selinexor (patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 of selinexor may enroll); active, unstable cardiovascular function, as indicated by the presence of symptomatic ischemia, uncontrolled clinically significant conduction abnormalities (e.g. patients with ventricular or atrial tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), congestive heart failure of NYHA class ≥ 3 or known left ventricular ejection fraction of \< 40%, or myocardial infraction within 3 months prior to C1D1 of selinexor therapy.
• Major surgery within 28 days prior to C1D1 of selinexor
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of C1D1 of selinexor.

Sponsors & Collaborators

• Washington University School of Medicine: lead
• Karyopharm Therapeutics Inc: collaborator

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

RECRUITING

Related Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

MeSH Terms

Conditions

Multiple Myeloma

Interventions

selinexor

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Mark A Schroeder, M.D.

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mark A Schroeder, M.D.

CONTACT

314-454-8306; markschroeder@wustl.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: September 30, 2025
• Study Start: March 17, 2026
• Primary Completion (Estimated): April 30, 2029
• Study Completion (Estimated): March 31, 2031
• Last Updated: June 8, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.
• Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Analysis will be performed to achieve the aims of the approved proposal. Contact the PI regarding proposal submission and accessing data.

Locations

US (1)